Category: Uncategorized

Research Triangle Park, NC, May 23, 2022 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that the Company will be participating in upcoming conferences.  The management team will also host one-on-one investor […]

Read More… from FENNEC PHARMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 If Approved by the FDA, PEDMARK™ Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children Company Has Approximately $18.3 Million in Cash and $5 Million of Funded Debt Research Triangle Park, NC, May 12, […]

Read More… from FENNEC PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

~ Prescription Drug User Fee Act (PDUFA) target action date set for September 23, 2022 ~ Research Triangle Park, NC, April 27, 2022 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s resubmitted New Drug Application (NDA) for PEDMARKTM (a unique formulation […]

Read More… from FENNEC PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE FOR FILING OF NEW DRUG APPLICATION RESUBMISSION FOR PEDMARK^TM

Research Triangle Park, NC, March 25, 2022 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that the Company will be participating in the 2022 Maxim Group Virtual Growth Conference, taking place March […]

Read More… from FENNEC PHARMACEUTICALS TO PARTICIPATE IN THE 2022 MAXIM VIRTUAL GROWTH CONFERENCE

Research Triangle Park, NC, March 24, 2022 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients one month to <18 years of […]

Read More… from FENNEC PHARMACEUTICALS RESUBMITS NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINSTRATION FOR PEDMARK^TM

~ Resubmission of NDA for PEDMARKTM Targeted for the First Quarter of 2022 ~ ~ Company has Approximately $21.1 Million in Cash and $5 Million of Funded Debt ~ Research Triangle Park, NC, February 28, 2022 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for […]

Read More… from FENNEC PHARMACEUTICALS ANNOUNCES FISCAL YEAR 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Research Triangle Park, NC, Jan. 31, 2022 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that Shubh Goel, the Company’s chief commercial officer, has tendered her resignation and will depart Fennec in […]

Read More… from FENNEC PHARMACEUTICALS ANNOUNCES MANAGEMENT CHANGE

RESEARCH TRIANGLE PARK, N.C., November 30, 2021 – Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that it received a Complete Response Letter (CRL) on November 29, 2021  from the U.S. Food and Drug Administration (FDA), after the PDUFA target action date of November 27, 2021, regarding its New Drug Application (NDA) for PEDMARKTM (a unique formulation […]

Read More… from Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors

~ FDA Pre-Approval Inspection Identified Deficiencies with the Facility of the Drug Product Manufacturer, Which Require Resolution Prior to PEDMARK Approval ~ RESEARCH TRIANGLE PARK, N.C., November 29, 2021 – Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that it expects to receive a Complete Response Letter (CRL) after the PDUFA target action date of […]

Read More… from Fennec Pharmaceuticals Expects to Receive Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors

FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 If Approved by the FDA, PEDMARKTM Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children Company Has Approximately $24 Million in Cash and Cash Equivalents Research Triangle Park, NC, November 10, 2021 – Fennec […]

Read More… from FENNEC PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE